Immunovaccine Inc., a clinical stage vaccine company, announced on Aug. 25 positive results for a vaccine formulated in its DepoVax technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH.
Immunovaccine Inc., a clinical stage vaccine company, announced on Aug. 25 positive results for a vaccine formulated in its DepoVax technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH.
In a preliminary study, four vaccinated cynomolgus macaque, which are particularly sensitive to the Ebola virus, received two doses of the DepoVax-formulated vaccine before being challenged with a lethal dose of the wild type Zaire strain of the Ebola virus. More than two weeks following exposure to the virus, all vaccinated subjects were alive with no disease symptoms. The two unvaccinated control animals in this study succumbed to the infection within seven days.
This study, conducted under NIAID’s preclinical services program was designed to identify favorable vaccine candidates for further study. Based on this high efficacy observed in cynomolgus macaques, Immunovaccine is exploring a potential development program for an Ebola virus vaccine with various organizations.
Source: Immunovaccine
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.